West Bancorporation Inc. Has $546,000 Stake in Eli Lilly and Company $LLY

West Bancorporation Inc. boosted its stake in Eli Lilly and Company (NYSE:LLY) by 24.1% in the second quarter, HoldingsChannel.com reports. The firm owned 701 shares of the company’s stock after buying an additional 136 shares during the period. West Bancorporation Inc.’s holdings in Eli Lilly and Company were worth $546,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Conning Inc. increased its holdings in Eli Lilly and Company by 11.0% in the second quarter. Conning Inc. now owns 10,429 shares of the company’s stock valued at $8,130,000 after purchasing an additional 1,033 shares during the period. Drucker Wealth 3.0 LLC grew its holdings in Eli Lilly and Company by 36.9% during the 2nd quarter. Drucker Wealth 3.0 LLC now owns 1,010 shares of the company’s stock worth $795,000 after acquiring an additional 272 shares during the period. Williams & Novak LLC acquired a new stake in Eli Lilly and Company during the 2nd quarter worth about $334,000. Eastern Bank grew its holdings in Eli Lilly and Company by 14.1% during the 2nd quarter. Eastern Bank now owns 123,674 shares of the company’s stock worth $96,408,000 after acquiring an additional 15,293 shares during the period. Finally, Lmcg Investments LLC grew its holdings in Eli Lilly and Company by 12.4% during the 2nd quarter. Lmcg Investments LLC now owns 11,312 shares of the company’s stock worth $8,818,000 after acquiring an additional 1,249 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

LLY stock opened at $833.08 on Friday. The company has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The business has a 50-day simple moving average of $742.42 and a two-hundred day simple moving average of $765.94.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Guggenheim raised their target price on Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $948.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.